Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) by pro-leu-gly-NH 2 (PLG; MIF-1)

Sheng, Jin; Xu, De Long; Yu, Hui Zhen; Xu, Xiu Rong; Tang, Qin

doi:10.1016/0024-3205(87)90291-8

Cited by 12 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After injection of tritiated MIF-1 into the lateral ventricle of rats, autoradiography has revealed specific accumulation of large amounts in the cells of the putamen and globus pallidus of the striatum [35]. The location by specific mass spectrometry of relatively high amounts of endogenous MIF-1 in the striatum is consistent with the activity of MIF-1 in animal models of Parkinson’s disease [3,8,13,23,37-41,51], including MPTP [30,47], as well as in clinical studies in patients with this disorder [2,18-20,45,48]. The striatum is also involved in mental depression [28,31,43,46], and known antidepressants are effective in some of the animal tests for Parkinson’s disease in which MIF-1 is active [22,23,37-41,51].…”

Section: Discussionmentioning

confidence: 89%

Mass spectrometric quantification of MIF-1 in mouse brain by multiple reaction monitoring

Kheterpal

Kastin

Mollah³

et al. 2009

Peptides

View full text Add to dashboard Cite

MIF-1 (Pro-Leu-Gly-NH2) has potent therapeutic effects in depression and Parkinson’s disease, but its CNS sites of production are not yet clear. In this study, the concentration of MIF-1 in different brain regions was measured by the multiple reaction monitoring technique on a 4000 QTRAP mass spectrometer. The limit of quantification was 300 fg of MIF-1, and limit of detection was 60 fg. The low molecular weight fractions of tissue homogenates from different regions of mouse brain were analyzed. The concentration of MIF-1 ranged from 22 ± 3 fg/μg protein in cerebral cortex to 930 ± 60 fg/μg protein in the hypothalamus. Moderate concentrations were also detected in all other regions tested, including the striatum, thalamus, and hippocampus. By incubation of stable isotope-labeled oxytocin with tissue preparations, it was also confirmed that oxytocin at least partially contributed to the production of MIF-1 in the hypothalamus by action of peptidases. Regional differences were also found. The results are the first to show the ultrasensitive quantification of MIF-1 in different brain regions, and support the neuromodulatory actions of MIF-1 in the striatum.

show abstract

Section: Discussionmentioning

confidence: 89%

Mass spectrometric quantification of MIF-1 in mouse brain by multiple reaction monitoring

Kheterpal

Kastin

Mollah³

et al. 2009

Peptides

View full text Add to dashboard Cite

show abstract

“…It exerts these effects even when given orally to mice and monkeys [27–29], and does not require the presence of the pituitary gland [1,24,28]. MIF-1 is also effective against the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) that induces many of the clinical symptoms of Parkinson’s disease [30,31]. In rats with unilateral substantia nigra lesions induced by 6-OHDA, peripheral injection of MIF-1 (2 ng/kg) potentiates the effect of L-dopa on apomorphine-induced turning, and it decreases endorphin levels in the caudate nucleus at a dose of 20 mg/kg [32].…”

Section: Conceptsmentioning

confidence: 99%

Concepts for Biologically Active Peptides

Kastin¹,

Pan²

2010

CPD

View full text Add to dashboard Cite

Here we review a unique aspect of CNS research on biologically active peptides that started against a background of prevalent dogmas but ended by exerting considerable influence on the field. During the course of refuting some doctrines, we introduced several concepts that were unconventional and paradigm-shifting at the time. We showed that (1) hypothalamic peptides can act ‘up’ on the brain as well as ‘down’ on the pituitary, (2) peripheral peptides can affect the brain, (3) peptides can cross the blood-brain barrier, (4) the actions of peptides can persist longer than their half-lives in blood, (5) perinatal administration of peptides can exert actions persisting into adulthood, (6) a single peptide can have more than one action, (7) dose-response relationships of peptides need not be linear, (8) the brain produces antiopiate as well as opiate peptides, (9) there is a selective high affinity endogenous peptide ligand for the mu-opiate receptor, (10) a peptide’s name does not restrict its effects, and (11) astrocytes assume an active role in response to metabolic disturbance and hyperleptinemia. The evolving questions in our laboratories reflect the diligent effort of the neuropeptide community to identify the roles of peptides in the CNS. The next decade is expected to see greater progress in the following areas: (a) interactions of peptides with other molecules in the CNS; (b) peptide involvement in cell-cell interactions; and (c) peptides in neuropsychiatric, autoimmune, and neurodegenerative diseases. The development of peptidomics and gene silencing approaches will expedite the formation of many new concepts in a new era.

show abstract

The IGF-I Amino-Terminal Tripeptide Glycine-Proline-Glutamate (GPE) Is Neuroprotective to Striatum in the Quinolinic Acid Lesion Animal Model of Huntington's Disease

Alexi

Hughes

Roon‐Mom

et al. 1999

Experimental Neurology

View full text Add to dashboard Cite

Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) by pro-leu-gly-NH 2 (PLG; MIF-1)

Cited by 12 publications

References 12 publications

Mass spectrometric quantification of MIF-1 in mouse brain by multiple reaction monitoring

Mass spectrometric quantification of MIF-1 in mouse brain by multiple reaction monitoring

Concepts for Biologically Active Peptides

The IGF-I Amino-Terminal Tripeptide Glycine-Proline-Glutamate (GPE) Is Neuroprotective to Striatum in the Quinolinic Acid Lesion Animal Model of Huntington's Disease

Contact Info

Product

Resources

About